Drug That Calms ‘Cytokine Storm’ Associated with 45% Lower Risk of Dying among COVID-19 Patients on Ventilators

Emily Somers, PhD, ScM leads team that finds patients who received a single intravenous dose of tocilizumab were 45% less likely to die overall, and more likely to be out of the hospital or off a ventilator one month after treatment.